Filtered By:
Specialty: Drugs & Pharmacology
Management: National Institutes of Health (NIH)

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 61 results found since Jan 2013.

The presence of Tau protein in blood as a potential prognostic factor in stroke patients.
Abstract Tau protein is found in the blood of 40 - 50% of patients in the acute phase of a stroke, as a result of the degradation of neurons and damage to the blood-brain barrier. The aim of the study was to assess the incidence of tau protein in the blood of stroke patients, as well as to evaluate the potential impact of tau protein presence in the blood of patients on their neurological state during the first 24 hours, and their functional condition three months after the stroke. Eighty-seven patients aged 39 - 99 (42 females and 45 males) diagnosed with stroke were enrolled in the prospective study (August 2014...
Source: J Physiol Pharmacol - September 30, 2016 Category: Drugs & Pharmacology Authors: A Lasek-Bal A, Jedrzejowska-Szypulka H, Rozycka J, Bal W, Kowalczyk A, Holecki M, Dulawa J, Lewin-Kowalik J Tags: J Physiol Pharmacol Source Type: research

Trial of a prehospital intervention with traditional Chinese medicine for acute stroke (TRACE): Protocol for a mixed-methods research study
Discussion: The results of the TRACE study will provide preliminary evidence for the relationship between XNJI used within 24 h of onset and the presence of END on the third day after stroke onset; it will aid in improving the current knowledge regarding the early use of XNJI for stroke first aid.Clinical Trial Registration:clinicaltrials.gov, identifier NCT04275349
Source: Frontiers in Pharmacology - August 29, 2022 Category: Drugs & Pharmacology Source Type: research

Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis 
.
Predictors of functional outcome and hemorrhagic complications in acute ischemic stroke patients treated with intravenous thrombolysis - A retrospective analysis
. Int J Clin Pharmacol Ther. 2017 Oct 26;: Authors: Zhao Q, Shan W, Liu L, Fu X, Liu P, Hu Y Abstract Intravenous thrombolysis (IVT) with recombinant tissue plasminogen activator (rt-PA) within 4.5 hours is an effective and routine therapy for acute ischemic stroke (AIS). The purpose of the study was to identify predictors of functional outcome at 3 months and hemorrhagic complications after IVT. A total of 123 AIS patients treated with in...
Source: International Journal of Clinical Pharmacology and Therapeutics - November 4, 2017 Category: Drugs & Pharmacology Tags: Int J Clin Pharmacol Ther Source Type: research

Intensive Versus Moderate Statin Therapy Discontinuation in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
This study aimed to clarify whether intensive statin therapy resulted in a significant increase in discontinuation early after discharge. METHODS: This multicenter registry study enrolled consecutive hospitalized patients with ischemic stroke or transient ischemic attack. All the patients were prescribed statin therapy at discharge. Intensity of statin therapy was defined according to the 2013 American College of Cardiology/American Heart Association guideline on the treatment of blood cholesterol. A logistic regression model was used to analyze the association between statin therapy intensity and discontinuation. ...
Source: Clinical Therapeutics - November 9, 2018 Category: Drugs & Pharmacology Authors: Yuan HW, Ji RJ, Lin YJ, Chen HF, Peng GP, Luo BY Tags: Clin Ther Source Type: research

Functional improvement and immune-inflammatory cytokines profile of ischaemic stroke patients after treatment with boswellic acids: a randomized, double-blind, placebo-controlled, pilot trial
AbstractIschaemic stroke represents one of the main causes of disability. According to the broad investigations, it is widely assumed that the contribution of inflammatory mediators is strongly involved in its pathogenesis. Hence, it seems that stroke treatment needs more efficient and inflammatory-targeted compounds to modulate inflammatory-related pathways. Such strategies paved the way to achieve better clinical outcomes along with conventional therapies. Boswellic acids (BAs), the main bioactive compounds ofBoswellia sp. resin; are triterpenoids with well-documented anti-inflammatory properties. Compared with NSAIDs, B...
Source: Inflammopharmacology - August 11, 2019 Category: Drugs & Pharmacology Source Type: research

Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage
AbstractIntracerebral hemorrhage (ICH) is a form of stroke characterized by uncontrolled bleeding into the parenchyma of the brain. There is no approved therapy for ICH and it is associated with very poor neurological outcomes with around half of subjects dying within 1  month and most subjects showing complete or partial disability. A key challenge is to identify subjects who could benefit from intervention using characteristics such as baseline hemorrhage volume and the increase in hemorrhage volume in the first few hours, which have been correlated with final o utcomes in ICH. Combined longitudinal models were develope...
Source: Journal of Pharmacokinetics and Pharmacodynamics - August 28, 2019 Category: Drugs & Pharmacology Source Type: research

Successful Intravenous Alteplase for a Centenarian Woman with Acute Ischaemic Stroke.
This article is protected by copyright. All rights reserved. PMID: 30697794 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Pharmacology and Physiology - January 29, 2019 Category: Drugs & Pharmacology Authors: He C, Sun Y, Yan B, Chen H, Zheng Y, Tang Y Tags: Clin Exp Pharmacol Physiol Source Type: research

Brilinta Approved in the US to Reduce the Risk of Stroke in Patients with an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
6 November 2020 -- AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health...
Source: Drugs.com - New Drug Approvals - November 6, 2020 Category: Drugs & Pharmacology Source Type: news

Alteplase for Acute Ischemic Stroke after Heparin Reversal with Protamine: A Case Report and Review
We describe the first reported case of a patient receiving full‐dose intravenous (IV) alteplase for AIS after heparin reversal with protamine. A 73‐year‐old man presented with AIS. He was treated with IV heparin, tirofiban, loading‐dose prasugrel, and aspirin before percutaneous coronary intervention (PCI) for placement of a right coronary artery stent. One hour following PCI, he abruptly developed left hemiparesis and dysphagia. The National Institutes of Health Stroke Scale was 12, and activated partial thromboplastin time (aPTT) was longer than 150 seconds. Head computed tomography (CT) showed no acute patholog...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - September 4, 2017 Category: Drugs & Pharmacology Authors: Gabriel V. Fontaine, Shawn M. Smith Tags: Case Report Source Type: research

Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial
In this study, we intend to use similar prescriptions that invigorate Qi and activate blood circulation: Buyang Huanwu granules (BHG), Naoxintong capsules (NXTC), and Yangyin Tongnao granules (YTG). The goal is to evaluate their level of PSC inpatients with IS with QDBS syndrome and find relevant biomarkers to provide an objective basis for precise treatment of TCM and improve the clinical therapeutic effects. A multicenter, randomized, double-blinded, and placebo-controlled intervention trial will be conducted in IS patients with QDBS syndrome, followed by an add-on of Chinese patent medicine. A total of 160 subjects will...
Source: Frontiers in Pharmacology - June 16, 2020 Category: Drugs & Pharmacology Source Type: research

The impact of SPRINT on the future treatment of hypertension: a mini review.
Authors: Chrysant SG Abstract Blood pressure (BP) control is associated with a significant decrease in the risk of coronary artery disease (CAD), stroke and chronic kidney disease (CKD), and U.S. treatment guidelines in 2003 and 2007 recommended a BP reduction to <140/90 mmHg for uncomplicated hypertension and to <130/80 mmHg for hypertension complicated by CAD, diabetes mellitus (DM) or CKD. In hopes of further decreasing the adverse effects of hypertension, more aggressive lowering of systolic blood pressure (SBP) was tested. However, this aggressive control of SBP did not materialize in additional cardiac ...
Source: Drugs of Today - May 19, 2016 Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research

YiQiFuMai Powder Injection Attenuates Coronary Artery Ligation-Induced Heart Failure Through Improving Mitochondrial Function via Regulating ROS Generation and CaMKII Signaling Pathways
This study was carried out in accordance with the recommendations of “Guide for the Care and Use of Laboratory Animals, National Institutes of Health.” The protocol was approved by the “China Pharmaceutical University.” Surgical Preparation The mice were anesthetized with chloral hydrate (4% chloral hydrate, ip). The HF model was induced by CAL as previously reported (Gao et al., 2010). Successful ligation of the coronary artery was confirmed by the occurrence of ST-segment elevation in electrocardiogram. Sham operated mice were performed the same process except left CAL. After ligation, the h...
Source: Frontiers in Pharmacology - April 9, 2019 Category: Drugs & Pharmacology Source Type: research

The effect of edaravone combined with DL-3-N-butylphthalide on the levels of tumor necrosis factor-alpha, interleukin-10, neuron-specific enolase and effect in patients with acute cerebral infarction
This study observed the effects of edaravone combined with Dl-3-N-butylphthalide (NBP) on the serum levels of tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10), and neuron-specific enolase (NSE), and its therapeutic effect in patients with acute cerebral infarction (ACI). The purpose of this study was to explore whether edaravone combined with NBP could improve the neurological function of patients with ACI. A total of 86 patients with ACI were enrolled in this study; 43 patients were randomly assigned to the control group and treated with edaravone only, while the other 43 patients were assigned to the interven...
Source: Journal of Physiology and Pharmacology - October 27, 2022 Category: Drugs & Pharmacology Authors: Q Q Shen W Wang H Wu X W Tong Source Type: research